Physician profile
Abdul M Khan
NPI 1356658116
$155,708.25
in general payments reported to CMS, 2019-2025
25 companies · $98K in 2025
The $98K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $298 · 2021: $681 · 2022: $1,242 · 2023: $6,404 · 2024: $49K · 2025: $98K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $71K · Honoraria: $53K · Travel and Lodging: $10K · Consulting Fee: $9,430 · Food and Beverage: $9,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,230.00 |
| Honoraria | $53,075.00 |
| Travel and Lodging | $10,261.28 |
| Consulting Fee | $9,430.00 |
| Food and Beverage | $9,201.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $93,698.31 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Axsome Therapeutics, INC. | $56,232.43 | 2023-2025 | Auvelity |
| Abbvie INC. | $978.74 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $623.26 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $589.74 | 2019-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $468.68 | 2020-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $402.02 | 2021-2025 | Ingrezza |
| Allergan, INC. | $364.06 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $351.44 | 2023-2025 | Fanapt, Hetlioz |
| Indivior INC. | $316.12 | 2021-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $302.26 | 2024-2025 | Cobenfy |
| Bausch Health US, LLC | $270.49 | 2021-2025 | Wellbutrin, Aplenzin |
| Otsuka America Pharmaceutical, INC. | $253.78 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $229.87 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $227.99 | 2019-2024 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $107.67 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $72.11 | 2022 | |
| Almatica Pharma LLC | $58.12 | 2022-2023 | Loreev Xr |
| Neuronetics, INC. | $38.47 | 2024-2025 | Neurostar Tms Therapy System |
| Luye Pharma (USA) LTD. | $35.94 | 2025 | Erzofri Extended-Release |
| Idorsia Pharmaceuticals US INC | $22.05 | 2023 | Quviviq |
| Eisai INC. | $17.05 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.92 | 2023 | Gvoke Hypopen |
| Avanir Pharmaceuticals, INC. | $16.72 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.